Naoshi Fukushima

This inventor holds 9 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 1998-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Naoshi Fukushima. Retrieved from https://idiyas.com/inventor/naoshi-fukushima

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 2)

% Patents Active = 55.6

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 1.7

ph-index = 6

Forward Citations = 102(Granted Patents)

Location History:

Gotemba, JP (2003 - 2010)
Shizuoka, JP (1998 - 2011)
Gotenba, JP (2012 - 2014)

Company Filing History:

9 out of 987

Chugai Seiyaku Kabushiki Kaisha

patents

Years Active: 1998-2014

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8759025 - Humanized anti-CD47 antibody (2014-06-24),

2. 8101719 - Humanized anti-CD47 antibody (2012-01-24),

3. 8025881 - BMP antibodies and methods of treating kidney disease using the same (2011-09-27),

4. 7696325 - Polypeptide inducing apoptosis (2010-04-13),

5. 7531643 - Monoclonal antibody inducing apoptosis (2009-05-12),

6. 6759043 - Monoclonal antibodies having property of causing apoptosis (2004-07-06),

7. 6579692 - Method of screening apoptosis inducing substances (2003-06-17),

8. 6267959 - Monoclonal antibodies having property of causing apoptosis and used as anticancer agents (2001-07-31),

9. 5840344 - Monoclonal antibodies having property of causing apoptosis (1998-11-24),

Title: Naoshi Fukushima: Innovator in Antibody Development

Introduction

Naoshi Fukushima is a prominent inventor based in Gotenba, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of 9 patents to his name, Fukushima's work is paving the way for advancements in therapeutic agents for hematological disorders.

Latest Patents

Fukushima's latest patents include a groundbreaking invention related to humanized anti-CD47 antibodies. This invention pertains to humanized antibodies that bind to CD47, as well as diabodies that also bind to human CD47. Notably, these diabodies are characterized by the presence of a disulfide bond between the fragments that form the diabody. The patents also cover genes encoding these antibodies, vectors containing said genes, and host cells that harbor these vectors. Furthermore, the processes for preparing these antibodies involve culturing the host cells, leading to the development of therapeutic agents for hematological disorders that incorporate these innovative antibodies.

Career Highlights

Fukushima is currently associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. His work at Chugai has allowed him to focus on cutting-edge research and development in the field of antibody therapeutics.

Collaborations

Fukushima collaborates with notable colleagues, including Shinsuke Uno and Yasufumi Kikuchi. Their combined expertise contributes to the advancement of innovative solutions in biotechnology.

Conclusion

Naoshi Fukushima's contributions to the field of antibody development are noteworthy and impactful. His innovative patents and collaborations highlight his commitment to advancing medical science. The work he is doing at Chugai Seiyaku Kabushiki Kaisha is set to make a significant difference in the treatment of hematological disorders.

Profile summary based on public USPTO records.